|
Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC. |
| |
|
Employment - AstraZeneca/MedImmune |
Stock and Other Ownership Interests - AstraZeneca/MedImmune |
| |
|
Employment - AstraZeneca/MedImmune |
Stock and Other Ownership Interests - AstraZeneca/MedImmune |
Research Funding - AstraZeneca/MedImmune |
| |
|
No Relationships to Disclose |
| |
|
Employment - AstraZeneca/MedImmune |
Stock and Other Ownership Interests - AstraZeneca/MedImmune |
Research Funding - AstraZeneca/MedImmune |
Patents, Royalties, Other Intellectual Property - AstraZeneca/MedImmune |
| |
|
Employment - AstraZeneca/MedImmune |
Stock and Other Ownership Interests - AstraZeneca/MedImmune |
| |
|
Employment - AstraZeneca/MedImmune |
Stock and Other Ownership Interests - AstraZeneca/MedImmune |
Patents, Royalties, Other Intellectual Property - AstraZeneca/MedImmune |
| |
|
Employment - AstraZeneca/MedImmune |
Stock and Other Ownership Interests - AstraZeneca/MedImmune |
| |
|
Employment - AstraZeneca/MedImmune |
| |
|
Employment - AstraZeneca/MedImmune |
Stock and Other Ownership Interests - AstraZeneca/MedImmune |
| |
|
No Relationships to Disclose |
| |
|
Employment - AstraZeneca/MedImmune |
Stock and Other Ownership Interests - AstraZeneca/MedImmune |
Patents, Royalties, Other Intellectual Property - AstraZeneca/MedImmune |